Home › Pathways › Cardiovascular & Metabolic Clinical Trials
❤️

Cardiovascular & Metabolic Clinical Trials

Cardiovascular disease and metabolic conditions are deeply interconnected — diabetes drives heart and kidney disease, obesity accelerates both, and hypertension underpins stroke risk. Clinical trials in this space are testing revolutionary drugs like GLP-1 agonists that address multiple conditions simultaneously.

6 Conditions 2 Treatments 5 Comparisons

The GLP-1 Revolution

GLP-1 receptor agonists, originally developed for type 2 diabetes, have demonstrated remarkable benefits beyond blood sugar control. Trials have shown significant weight loss, cardiovascular protection, and kidney benefits. The SELECT trial showed semaglutide reduces major cardiovascular events by 20% in obese patients without diabetes. UK trials continue to explore new GLP-1 combinations and indications.

Heart Failure Treatment Advances

Heart failure trials have seen a surge of innovation. SGLT2 inhibitors (originally diabetes drugs) are now standard heart failure treatment based on landmark trials. New trials are testing cardiac gene therapy, novel diuretics, and device-based approaches including baroreceptor activation therapy and cardiac contractility modulation.

Prevention and Early Intervention

An increasing number of UK cardiovascular trials focus on prevention — intervening before disease develops. These include lifestyle intervention studies, polypill trials, and precision medicine approaches using genetic risk scores to target prevention at high-risk individuals. If you have risk factors but not yet diagnosed disease, prevention trials may be available.

📋 Conditions

💊 Treatments

⚖️ Comparisons

📰 Related Articles

Frequently Asked Questions

Can I join a diabetes trial if I am newly diagnosed?
Yes. Many trials specifically recruit newly diagnosed patients to test early intervention strategies. The NHS Diabetes Prevention Programme also collaborates with research networks to offer trial participation to people at high risk of developing type 2 diabetes.
Are GLP-1 agonists available through clinical trials?
Yes. While GLP-1 agonists like semaglutide are approved for diabetes and obesity, many trials are testing next-generation versions, new combinations, and expanded indications including cardiovascular and kidney disease prevention.

Find Your Clinical Trial

Search thousands of actively recruiting trials across the UK — free, instant, no registration.

Search Trials Now Read the Guide